지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
초록· 키워드
오류제보하기
Background: Recently, a fixed combination of grazoprevir and elbasvir (GE) has been introduced to the arsenal ofchemotherapeutics to fight against this virus. The study aimed to provide information on the efficacy and safety of GE for thetreatment of HCV infection by performing a meta-analysis of literature data. Methods: PubMed and EMBASE database searcheswere conducted. Among the literature retrieved, pivotal Phase III clinical studies were analyzed. Statistical analysis of the data wasperformed by RevMan. Results: Four pivotal Phase III clinical studies compared the efficacy and safety of GE. When HCV patientswere treated with GE for 12 weeks, the sustained virologic response, defined as the viral RNA level below the lower limit ofquantification at 12 weeks after the cessation of therapy (SVR12), was 94.7%. The clinical advantage of GE involves its use bypatients with cirrhosis and/or renal failure without dose adjustment. If the genotype (GT) of the causative virus was GT1a with NS5Apolymorphism or GT4 with resistance to peginterferon/ribavirin, treatment with GE plus ribavirin for 16 weeks resulted in a betteroutcome compared to treatment with GE alone for 12 weeks. Adverse events reported during the four clinical studies were 71.09%in the GE arms and it was 76.61% in the non-GE arms, with the most frequent events being mild central nervous system symptoms.
Conclusion: GE was generally safe and effective for the treatment of HCV infection. However, since HCV mutates very rapidly andbecomes resistant to antiviral agents, long-term monitoring should be mandatory.
목차
등록된 정보가 없습니다.
참고문헌 (24)
참고문헌 신청
AASLD and IDSA HCV Guidance Panel / 2015 / Hepatitis C guidance:AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus / Hepato
Alric L / 2016 / Grazoprevir + elbasvir for the treatment of hepatitis C virus infection / Expert Opin Pharmacother 17 : 735 ~ 742
Banerjee D / 2016 / Review article: safety and tolerability of directacting anti-viral agents in the new era of hepatitis C therapy / Aliment Pharmacol Ther 43 : 674 ~ 696
Cacoub P / 1999 / Extrahepatic manifestations of chronic h
Carrion AF / 2016 / Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C / Expert Opin Drug Saf 15 : 883 ~ 890
Alric L / 2016 / Grazoprevir + elbasvir for the treatment of hepatitis C virus infection / Expert Opin Pharmacother 17 : 735 ~ 742
Banerjee D / 2016 / Review article: safety and tolerability of directacting anti-viral agents in the new era of hepatitis C therapy / Aliment Pharmacol Ther 43 : 674 ~ 696
Cacoub P / 1999 / Extrahepatic manifestations of chronic h
Carrion AF / 2016 / Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C / Expert Opin Drug Saf 15 : 883 ~ 890
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
증숙 횟수에 따른 천마 추출물의 피부 생리 활성 평가
대한본초학회지(본초분과학회지)
2018 .01
-
An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection
Clinical and Molecular Hepatology
2019 .01
-
Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals
Clinical and Molecular Hepatology
2018 .01
-
석고 추출물의 미백 효과
한방안이비인후피부과학회지
2020 .01
-
Recent developments in endoscopic ultrasonography-guided gastroenterostomy
International Journal of Gastrointestinal Intervention
2020 .01
-
Hepatitis C Viral Infection in Children: Updated Review
Pediatric Gastroenterology, Hepatology & Nutrition
2016 .01
-
Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study
Clinical and Molecular Hepatology
2018 .01
-
C형 간염의 역학
대한내과학회지
2015 .01
-
Clinical Characteristics and Treatment Outcome of Peginterferon Plus Ribavirin in Patients Infected with Genotype 6 Hepatitis C Virus in Korea: A Multicenter Study
Gut and Liver
2017 .01
-
Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection
Clinical and Molecular Hepatology
2019 .01
-
Hepatitis C Virus and Antiviral Drug Resistance
Gut and Liver
2016 .01
-
Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C
Journal of Korean Medical Science
2016 .01
-
특수한 경우의 C형 간염 치료: 만성 콩팥병
대한내과학회지
2015 .01
-
Use of direct antiviral agents in liver transplant recipients with hepatitis C virus in Korea : 2-center experience
Annals of Surgical Treatment and Research
2018 .09
-
Cost-effectiveness of chronic hepatitis C screening and treatment
Clinical and Molecular Hepatology
2022 .04
-
Endoscopic Ultrasonography-Guided Gastroenterostomy Techniques for Treatment of Malignant Gastric Outlet Obstruction
Clinical Endoscopy
2020 .01
-
Recognition criteria for occupational cancers in relation to hepatitis B virus and hepatitis C virus in Korea
대한직업환경의학회지
2018 .01
-
The Korean Hepatitis C Virus Care Cascade in a Tertiary Institution: Current Status and Changes in Testing, Link to Care, and Treatment
Gut and Liver
2022 .11
-
Epidemiological and Clinical History of Viral Hepatitis in Korea
Infection and Chemotherapy
2021 .01
-
Toward hepatitis C virus elimination using artificial intelligence
Clinical and Molecular Hepatology
2024 .04
이 논문의 저자 정보
최근 본 자료
댓글(0)
0